Protalix: Clinical Trials

17 trials sponsored by Protalix, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

13 completed, 2 unknown, 1 recruiting, 1 withdrawn. 7 Phase 1, 6 Phase 2, 4 Phase 3, 1 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 1	7	Completed 7
Phase 2	6	Completed 3, Unknown 2, Recruiting 1
Phase 3	4	Completed 3, Withdrawn 1
Early Phase 1	1	Completed 1

Follow Protalix: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) PRX-115, Methotrexate (MTX), PRX-115 placebo - Gout	Phase 2	Recruiting	Protalix	150	2025-12-22	2026-09-29
A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels PRX-115, Placebo - Gout	Phase 1	Completed	Protalix	64	2023-03-23	2025-02-11
Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion Interview - Fabry Disease		Completed	Chiesi Farmaceutici S.p.A.	23	2022-01-26	2023-03-21
Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks Pegunigalsidase alfa - Fabry Disease	Phase 3	Completed	Protalix	30	2017-07-10	2023-09-13
Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease PRX-102, Placebo - Fabry Disease	Phase 3	Withdrawn	Protalix		2017-07-01	2018-01-08
Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa) PRX-102 (pegunigalsidase alfa) - Fabry Disease	Phase 3	Completed	Protalix	22	2017-05-17	2023-09-13
Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis OPRX-106 - Ulcerative Colitis	Phase 2	Unknown	Protalix	20	2016-09-01	2016-09-28
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function PRX-102 (pegunigalsidase alfa), agalsidase beta - Fabry Disease	Phase 3	Completed	Protalix	78	2016-06-01	2023-09-13
Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme® AIR DNase™ - Cystic Fibrosis	Phase 2	Unknown	Protalix	15	2016-05-01	2016-09-28
Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers AIR DNase, Placebo - Cystic Fibrosis (CF)	Phase 1	Completed	Protalix	18	2015-12-01	2016-05-17
Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers OPRX-106 - Human Volunteer	Phase 1	Completed	Protalix	18	2014-07-01	2015-08-05
An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 PRX-112 - Gaucher Disease	Phase 2	Completed	Protalix	10	2014-04-01	2016-09-28
Extension Study of PRX-102 for up to 60 Months PRX-102 (pegunigalsidase alfa) - Fabry Disease	Phase 1 / Phase 2	Completed	Protalix	15	2014-01-16	2023-09-13
Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients PRX-112 - Gaucher Disease	Phase 1	Completed	Protalix	16	2013-03-01	2014-04-07
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients PRX-102 - Fabry Disease	Phase 1 / Phase 2	Completed	Protalix	18	2012-10-01	2023-09-13
An Exploratory Phase 1 Microdose Study of PRX-105 PRX-105 - Organophosphate Exposure	Early Phase 1	Completed	Protalix	10	2010-03-01	2012-09-05
Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD) Human Glucocerebrosidase (prGCD) - Gaucher Disease	Phase 1	Completed	Protalix	6	2005-11-01	2006-12-05

Conditions studied

Interventions

Countries

Top investigators

Results publications